Compare Abeona Therapeutics Inc (ABEO) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while JPMorgan Diversified Return International Eqty ETF trades at $72.26. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, JPMorgan Diversified Return International Eqty ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | JPIN | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $76.96 |
52-Week Low | $4.17 | $63.14 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JPIN trades at $73.74, up 0.49% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides broad exposure to international value stocks. A dividend of $0.91 per share is scheduled for payment on June 25, 2026.
Outlook remains cautiously optimistic given bullish technical trends, though overbought RSI signals near-term risk. Key risks include international market volatility and currency fluctuations. The dividend provides income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
